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Type 1 diabetes is recognized as an autoimmune inflammatory disease and low grade inflammation is also observed in type 2 diabetic
patients. Interleukin 17 (IL-17) is a new player in inflammation.Th17 cells, as the main source of IL-17, require transforming growth
factor 𝛽 (TGF-𝛽) and interleukin 23 (IL-23).The aim of this study was to investigate serum IL-17, IL-23 and TGF-𝛽 levels in diabetic
patients and controls. In this case-control study, serum levels of IL-17, IL-23, and TGF-𝛽weremeasured in 24 type 1 diabetic patients
and 30 healthy controls using the ELISAmethod. Simultaneously, the samemethodologywas used to compare serum concentration
of these three cytokines in 38 type 2 diabetic patients and 40 healthy controls. There was no significant difference between serum
levels of IL-17 and IL-23 cytokines between cases and controls. However, TGF-𝛽 was significantly lower in type 1 diabetic patients
(𝑃 < 0.001). Serum IL-17 and IL-23 levels demonstrate no association with type 1 and type 2 diabetes, but, in line with previous
studies, TGF-𝛽 levels were lower in type 1 diabetic patients.
1. Introduction
Growing medical literature refers to increasing incidence of
type 1 diabetes (T1D) [1]. T1D is recognized as an autoimmune
disease [2]. Due to immune mediated pancreatic 𝛽-cell
destruction, 𝛽-cell mass and function are decreased [3] and
insulin dependence occurs. It seems both immune cells [4]
and inflammatory mediators such as cytokines have roles
in 𝛽-cell destruction. Alteration of inflammatory mediator
levels like interleukin 1 beta (IL-1𝛽), interleukin 6 (IL-6),
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tumor necrosis factor alpha (TNF-𝛼), and C-reactive protein
(CRP) is a characteristic of T1D [5–7]. Evidence is also accu-
mulating to suggest low-grade systemic inflammation in type
2 diabetes (T2D) in which concentration of inflammatory
cytokines such as IL-1𝛽 increases. IL-6 has been inferred as
the other player in developing insulin resistance and T2D [8].
It seems inflammation is a common feature of type 1 and type
2 diabetic patients.
A newly described inflammatory cytokine, interleukin
17 (IL-17A), was discovered as CTLA-8 in 1993 [9] and
it took about 10 years to identify the cellular source of
this cytokine to be Th17 cells [10]. Increasing evidence
has indicated an established role of Th17 cells in different
autoimmune diseases such as systemic psoriasis, rheumatoid
arthritis, inflammatory bowel disease, lupus erythematosus,
and multiple sclerosis [11]. Data obtained from human T1D
studies and mouse models suggest involvement of Th17
cells and IL-17 in T1D pathogenesis. Marwaha et al. [12]
have shown increased proportion of a CD4+ T-cell subset
secreting higher levels of IL-17 in subjects with new-onset
T1D. Application of a neutralizing anti-IL-17 in nonobese
diabetic mice (NOD) by Emamaullee et al. prevented dia-
betes, suggesting Th17 cell involvement in T1D pathogenesis
[13].
Development of a Th17 cell population depends on a
combination of cytokines. One such cytokine is transforming
growth factor beta (TGF-𝛽). Human transforming growth
factor-𝛽1 (TGF-𝛽1) belongs to a protein family including a
large number of highly conserved and structurally related
proteins. Members of this family are involved in tissue
homeostasis and embryogenesis [14]. TGF-𝛽1 is a multi-
functional cytokine with context dependent actions. It may
exert either immunosuppressive or inflammatory effects.
Both arms of the immune system are inhibited by regulatory
effects of this cytokine [15]. This cytokine plays a major
role in tolerance maintenance through controlling survival,
proliferation, and differentiation of T lymphocytes. TGF-
𝛽1 is also able to inhibit B-cell proliferation or block B-
cell activation by inducing apoptosis [16]. TGF-𝛽1 is also
recognized as a proinflammatory cytokine due to its involve-
ment in Th-17 cell differentiation. In 2006, three different
groups [17–19] demonstratedTh17 development by TGF-𝛽 in
combination with IL-6. In this context, significance of TGF-
𝛽 is controversial. While the study conducted by Veldhoen
et al. [18] indicated that the antagonistic effect of TGF-𝛽
on development of Th1 and Th2 was not the only role that
this cytokine played in Th17 development, Das et al. [20]
believe there is an indirect role for this cytokine in Th17
differentiation. The second effective cytokine in TH17 cell
development is interleukin 23 (IL-23). It seems IL-23 is not
involved in initiation of Th17 differentiation since it has no
receptor on naive T cells. However, its upregulation after the
initiation phase suggests its important role for maintenance
of Th17 cells [21].
To clarify whether serum levels of IL-17 demonstrate a
change in T1D and T2D, we compared its concentration in
the sera of 24 type 1 and 38 type 2 diabetic patients and
age-matched healthy controls. Serum concentrations of IL-
23 and TGF-𝛽were also measured in the same group because
Table 1: Type 1 diabetes study subjects characteristics.
Variables Case Control
𝑛 = 24 𝑛 = 30
Age (years) 17.96 ± 7.29 18.53 ± 8.38
Sex (M/F) 9/15 18/12
BMI (kg/m2) 21.09 ± 4.04 22.6 ± 3.39
FBS (mg/dL) 180.38 ± 99.19 88.3 ± 8.14
Chol (mg/dL) 160.88 ± 39.11 163.35 ± 16.31
TG (mg/dL) 87.69 ± 32.48 97.76 ± 32.46
HDL (mg/dL) 53.44 ± 16.61 50.82 ± 8.52
LDL (mg/dL) 86.5 ± 26.35 88.24 ± 14.32
M: male, F: female, BMI: body mass index, FBS: fasting blood glucose, Chol:
cholesterol,
TG: triglyceride, HDL: high-density lipoprotein, and LDL: low-density
lipoprotein.
Data are presented as mean ± SD.
development and maintenance of Th17 cells, as the main
source of IL-17, require these two cytokines.
2. Materials and Methods
2.1. Participants. Blood from 24 diabetic patients, aged 6 to
30 years, was collected at theDiabetes andMetabolicDiseases
Clinic, and serum samples of 30 healthy subjects in the same
age groups were collected at the Children Medical Center
Hospital and FarmanfarmaianHealth Center, TehranUniver-
sity of Medical Sciences (TUMS). Children were brought to
the hospital for preschool health monitoring plan or prior to
circumcision. Healthy children were chosen based on lack of
prior medical history, lack of prescribed medication use, and
normal test results. Adults were referred to the health center
for annual occupational monitoring. Healthy adults lacked
prior medical history or medication use (prescription or
otherwise) and had normal test results (Table 1). Subsequent
to selection of our healthy control group, C-reactive protein
test was conducted. T1D was diagnosed based on American
Diabetes Association (ADA) criteria. T1D patients were
questioned in detail about any T1D complications or any
other pathology other than T1D. Patients suffering from T1D
complications or any other pathology were excluded from
the study. The only medication taken by type 1 diabetic
patients in our study was insulin. Study subjects’ background
information such as age, weight, and height was recorded.
Blood from 38 T2D patients and 40 adult healthy con-
trols, aged 30 to 65 years, was taken from Farmanfarma-
ian Health Center, Tehran University of Medical Sciences
(TUMS).These subjects were referred to the health center for
annual occupational monitoring, participated in the diabetes
screening project, or required periodical biochemistry tests
for monitoring purposes. Healthy controls were chosen
according to the above mentioned criteria (Table 2). T2D
patients were recruited based on their fasting blood glucose
and medical history. All diabetic patients with diabetic
complications, diabetes duration of more than five years, or
any other pathology other than T2D were excluded from
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Table 2: Type 2 diabetes study subjects characteristics.
Variables Case Control 𝑃 value
𝑛 = 38 𝑛 = 40
Age (years) 51.14 ± 8.63 34.98 ± 11.39 0.001
Sex (M/F) 19/19 22/18
BMI (kg/m2) 27.39 ± 4.32 24.58 ± 4.14 0.007
FBS (mg/dL) 155.21 ± 55.6 86.12 ± 7.44 0.001
Chol (mg/dL) 190.59 ± 44.63 167.63 ± 16.92 0.01
TG (mg/dL) 234.57 ± 264.72 98.73 ± 36.93 0.002
HDL (mg/dL) 44.5 ± 13.03 52.48 ± 9.83 0.003
LDL (mg/dL) 101.42 ± 27.29 93.15 ± 17.23 0.1
M: male, F: female, BMI: body mass index, FBS: fasting blood glucose, Chol:
cholesterol,
TG: triglyceride, HDL: high-density lipoprotein, and LDL: low-density
lipoprotein. Data are presented as mean ± SD.
Table 3: Cytokine serum levels in cases and controls of type one
diabetes.
Cytokine Case Control 𝑃 value
Median (IQR) Median (IQR)
IL-17 4.93 (7.37) 2.61 (7.87) 0.15
IL-23 0 (4.47) 0.70 (9.1) 0.08
TGF-𝛽 0 (0) 184.52 (627.22) 0.001
Interquartile range (IQR): 75th–25th.
Table 4: Cytokine serum levels in cases and controls of type two
diabetes.
Cytokine Case Control 𝑃 value
Mean ± SD Mean ± SD
IL-17 6.61 ± 4.97 6.22 ± 4.64 0.8
IL-23 15.2 ± 4.07 38.22 ± 10.94 0.3
TGF-𝛽 50.46 ± 72.62 84.76 ± 72.62 0.1
the study. Eight of the T2D patients used metformin and/or
glibenclamide.
Serum samples were collected and stored at −70∘C and
biochemical tests were done for all subjects. Fasting blood
glucose (FBS), total cholesterol, high-density lipoprotein
cholesterol (HDL), and triglyceride (TG) were measured
using AutoAnalyzer (Hitachi902, Japan). Using a commercial
kit (Parsazmun, Iran), low-density lipoprotein (LDL) was
measured. This study was approved by the ethics committee
of TUMS and informed consent was obtained from all
participants.
2.2. Cytokine Assays. Serum concentrations of IL-17, IL-
23, and TGF-𝛽 were measured using commercially avail-
able enzyme-linked immunosorbent assay kits (eBioscience
ELISA kits, USA). Sensitivity of the kits for these cytokines
was 4 picogram per milliliter (pg/mL) for IL-17, 15 pg/mL
for IL-23, and 60 pg/mL for TGF-𝛽. In brief, Maxisorp
immunoplates (Nunc, Denmark) were coated with mono-
clonal antibodies (mAb) specific for IL-17, IL-23, and TGF-𝛽.
Then, serum samples and standards were added and serum
cytokines were detected using biotinylated mAb specific for
IL-17, IL-23, and TGF-𝛽 followed by addition of streptavidin-
horseradish peroxidase and color development. Activation of
serumTGF-𝛽was conducted according to themanufacturer’s
instructions. Absorbance was read at 450 nm. Using standard
curves, the values were expressed in pg/mL.
2.3. Statistical Analysis. All data are presented as mean ±
SD unless otherwise stated. Normal distribution of type one
diabetes data was assessed by Kolmogorov-Smirnov test. To
compare continuous variables between groups, Student’s t-
test and Mann-Whitney U test were applied. In all analyses,
𝑃 values < 0.05 were considered as statistically significant. All
statistics were done using SPSS for windows version 15.
3. Results
This study was conducted to investigate IL-17 levels in serum
of patients with T1D and T2D. Serum concentrations of
TGF-𝛽 and IL-23 were also defined, since development and
maintenance ofTh17 cells, as themain source of IL-17, require
these two cytokines.
Background information and biochemical characteristics
of all participants are summarized in Tables 1 and 2. In T1D,
serum FBS level was the only biochemical factor showing
significant difference between case and control groups (𝑃 <
0.001). In T2D, all biochemical factors except LDL were
significantly different between case and control groups.
Serum levels of IL-17 were detectable in most samples
while concentration of TGF-𝛽 and especially IL-23 in many
sera was lower than the detection limit of the kits and in
statistical analysis they have been considered to be zero since
signal values for these samples were as low as signal values for
blankwells during the test. Results are summarized in Figure 1
and Tables 3 and 4.
Statistical analysis showed a significant difference
between serum levels of TGF-𝛽 in type one diabetic patients
and healthy controls (𝑃 < 0.001). No statistical difference
was observed in terms of IL-17 and IL-23 serum levels
between the two groups (Tables 3 and 4). Intergroup
statistical analysis was not possible due to small sample size.
Comparison between healthy controls of the two groups
(type one and type two diabetes) indicated a statistically
significant difference between serum levels of TGF-𝛽
(𝑃 < 0.001).
4. Discussion
In the present study, comparison of IL-17 and IL-23 levels in
serum of diabetic patients compared with healthy controls
showed no significant difference while TGF-𝛽 level was
lower in serum of type 1 diabetic patients. Decreased levels
of TGF-𝛽 gene expression and protein secretion in T1D
have been reported previously [22–26]. In the current study,
TGF-𝛽 levels were detectable in almost 70% of healthy
controls and 20% of type 1 diabetic patients. This can be a
reflection of overall reduced levels of TGF-𝛽 in the disease
state as supported by our statistical analysis. Interestingly,
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glucose affects TGF-𝛽 levels. Hyperglycemia stimulates TGF-
𝛽 expression in different cell types such as macrophages [27],
human mesenchymal stem cells [28], and mouse mesangial
cells [29]. Elevated levels of TGF-𝛽 gene expression have been
reported in patients with type 2 diabetes [26], and this is in
line with effect of high concentrations of glucose on different
cells. Regarding the abovementioned findings, reduced levels
of TGF-𝛽 in T1D seem intriguing. Different cell types such
as dendritic cells and naturally occurring regulatory T cells
(nTregs) can produce TGF-𝛽 under different immunolog-
ical conditions. TGF-𝛽 is an essential cytokine for nTreg
development and function [30]. nTregs have a central role
in prevention of T1D development and a major mechanism
applied to delay T1D onset by nTregs is TGF-𝛽 secretion [31].
Functional defect related to signaling pathways leading to
TGF-𝛽 production in these cells or other TGF-𝛽 sources in
T1D may be the reason for the reduced levels of the cytokine.
It seems that this fundamental change cannot be affected by
high concentrations of glucose.
Our data indicated that serum TGF-𝛽 levels were higher
in the T1D control group in comparison with the T2D
control group. While T1D mainly strikes children and
younger adults, T2D is commonly observed in adulthood. To
exclude the age related variations, two age-matched healthy
control groups with mean age of 18.53 and 34.98 years
were separately selected for T1D and T2D patients, respec-
tively. The mean concentration of TGF-𝛽 was significantly
higher in T1D controls (younger controls) in comparison
to other three groups including T1D patients, T2D patients,
and T2D control groups (Figure 1). T1D and its control
group were matched for several factors (Table 1) including
age and the sole documented criteria for exception were
FBS as a marker of diabetes. Due to the fact that we
had tried to control measurable factors, it appeared logical
to suspect that the significant difference observed in the
level of serum TGF-𝛽 could be related to diabetes and
this finding was in accordance with previous observations
[22–26].
Comparing the two control groups indicated that the
only significant difference between them was their age.
The efficiency of the immune system declines with age.
This gradual systemic failure has a multifactorial etiology
including genetic and environmental factors. In the year
2000, Franceschi et al. [32] coined “Inflammaging” to refer
to a proinflammatory status which is a main characteristic
of aging. Several epidemiologic studies have established an
association between aging and some inflammatory markers
specially IL-6, TNF-𝛼, andCRP [33]. A research conducted by
McFarlane et al. [34] indicated that age-related inflammatory
changes including rise in the level of CRP, IL-6, and ratio of
IL-6 to interleukin 10 (IL-10) occur in baboons. On the other
hand, Willis et al. [35], using a baboon model, have shown
that serum TGF-𝛽 reduction is associated with age in female
baboons.
These findings give rise to questions regarding the level
of regulatory cytokines such as TGF-𝛽 in aging. It would be
interesting to know if there is any change in TGF-𝛽 level
during human lifespan. If so, can this change affect inflam-
maging? Lin et al. [36] found that TGF-𝛽 level reduction was
age dependent and this reduction was inversely associated
with age. Since their study group aged between 40 and 80
years, they could not follow TGF-𝛽 reduction trend in people
aged below 40 years. Our data indicated that this trend can
be observed in younger people and this finding is in line with
results obtained by Okamoto et al. [37] who compared serum
TGF-𝛽 levels between healthy subjects aged between 1 and
14 years and 21 and 67 years. Inverse association between
TGF-𝛽 and age is controversial since this association was not
observed byGrainger et al. [38]. Reduction of IL-10 as an anti-
inflammatory cytokine in healthy old people has also been
reported by Saurwein-Teissl et al. [39] who underscored an
imbalance of pro- and anti-inflammatory cytokines in elderly
people. This inconsistency in cytokine network may lead to
age-related diseases with low grade inflammation such as
diabetes.
Increasing data suggest a pathogenic role for Th-17 cells
in autoimmune and inflammatory diseases. Role of these cells
in T1D pathogenesis has been investigated by several groups.
Bending et al. [40] believeTh17 cells play their role in disease
through their plasticity towards aTh-1 like profile. A study by
Martin-Orozco et al. [41] in NODmice has shown thatTh-17
cells play a role in inflammation of pancreas; however, for T1D
induction, conversion of these cells to Th-1 cells is necessary.
Other mechanisms have also been suggested to shed light
on the role of these cells in T1D. It seems that increased
number ofTh-17 cells results in an imbalance between nTregs
and effector T cells and autoimmunity [42]. We could detect
IL-17 in most tested sera. Observation of no significant
difference between cases and controls may be consistent with
the above mentioned findings and there is lack of evidence
for a role that these cells may play in T1D and T2D systemic
inflammation.
In our study, IL-23 serum levels were undetectable in
most cases and controls and there were no significant differ-
ences between serum concentrations in diabetic patients and
healthy controls. Langrish et al. [43] refer to the role of IL-23
in Th-17 development and its indirect effect in autoimmune
inflammatory diseases. This role has been investigated in
a recent study by Mus et al. [44], which have shown IL-
23 cytokine effect on promotion of Th-17 cell development
in autoimmune experimental arthritis. Evidence for IL-
23 involvement in Th-17 cell maintenance has also been
presented [21]. Destructive effect of IL-23 administration on
pancreatic𝛽-cells leading to hyperglycemia in amousemodel
[45] refers to a possibly direct role of IL-23 in autoimmune
diabetes. Our goal of IL-23 serum level measurement was
to detect any change in the cytokine concentration in dia-
betic patients’ sera. Regarding the number of samples with
cytokine levels below the detection limit, it seems that it
is better to use a more sensitive method for the cytokine
assay in serum samples. In the present study, the difference
between serum levels of this cytokine in healthy subjects
and T1D patients was close to being significant (𝑃 = 0.08).
Abbasi et al. [26] have shown upregulation of IL-23 gene in
unstimulated peripheral blood mononuclear cells (PBMCs)
in T1D. It appears a larger sample size and a more sensitive
method should be applied to study the role of this cytokine in
T1D.
BioMed Research International 5
Ca
se
 T
1
D
C
on
tro
l T
1
D
Ca
se
 T
2
D
C
on
tro
l T
2
D
0
200
400
600 ∗∗∗
∗∗∗
TGF-𝛽
TG
F-
𝛽
co
nc
en
tr
at
io
n 
(p
g/
m
L)
(a)
IL
-1
7
co
nc
en
tr
at
io
n 
(p
g/
m
L)
Ca
se
 T
1
D
C
on
tro
l T
1
D
Ca
se
 T
2
D
C
on
tro
l T
2
D
IL-17
8
6
4
2
0
(b)
IL
-2
3
co
nc
en
tr
at
io
n 
(p
g/
m
L)
Ca
se
 T
1
D
C
on
tro
l T
1
D
Ca
se
 T
2
D
C
on
tro
l T
2
D
IL-23
20
15
10
5
0
(c)
Figure 1: Serum TGF-𝛽, IL-17, and IL-23 levels in T1D and T2D patients and healthy controls. TGF-𝛽 levels were significantly lower in T1D
patients than controls. Comparison of TGF-𝛽 level between two control groups indicated it was lower in the T2D control group ( ∗∗∗𝑃 <
0.001). Data are presented as mean ± SEM.
A minor point in our study was that serum LDL levels
in T2D patients were similar to healthy control LDL levels.
It is common to observe elevated levels of serum TG and
decreased levels of HDL in T2D patients while LDL shows
no change or even reduction due to the dysregulation of
lipoprotein lipase which is involved in LDL synthesis [46].
In summary, our results suggest that serum IL-17 and IL-
23 levels were not affected in diabetic patients whereas TGF-
𝛽 was significantly decreased in T1D. Although the present
study does have weaknesses which may be recognized in
primary studies of novel entities, to the best of our knowledge,
this is one of few studies so far conducted to elucidate the
potentially significant role IL-17 and IL-23 could play in
diabetes in humans. Though ELISA is a common method
to measure cytokine levels, it appears that it is not sensitive
enough for measurement of IL-23 in serum. Low sensitivity
of the applied technique in the present study was not suffi-
ciently rigorous to allow definitive illustration of a significant
relationship or lack of a significant relationship between these
two potentially important cytokines and diabetes. Further
efforts should be devoted to finding more sensitive methods
to assay serum cytokine levels to clearly delineate possible
systemic involvement of these cytokines in diabetes. Findings
in this study show that the difference between T1D patients
and their age-matched controls in terms of serum TGF-𝛽
concentration is mostly related to the disease status because
patients and controls have been matched for notable criteria
such as age. Meanwhile, the higher concentration of TGF-𝛽
in younger control individuals compared to the older controls
seems to bemost logically an age-related issue (if for nowonly
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giving consideration to measurable factors) and evidence is
accumulating that physiological TGF-𝛽 concentrations show
reduction later in life. Association between TGF-𝛽 and age is
controversial and further studies/data to clarify this possible
relationship can be enlightening. Alsomore investigations are
necessary to clarify the mechanism of TGF-𝛽 reduction in a
hyperglycemic milieu.
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